In the August issue of Gastroenterology & Endoscopy the following hepatology experts: Nezam Afdhal, MD, Stuart C. Gordon, MD and Ira Jacobson, MD comment on their favorite abstracts from this year's liver meeting.
Experts' Picks: Best of the EASL/International Liver Congress 2012
Hepatology in Focus
Compiled and written by David Wild
Gastroenterology & Endoscopy News asked several hepatology experts to select their favorite abstracts from this year’s European Association for the Study of the Liver/International Liver Congress, held in Barcelona.
Abstracts:
Safety of Telaprevir or Boceprevir in Combination with Peginterferon alfa/Ribavirin in Cirrhotic non-Responders: First Results of the French Early Access Program (ANRS C020-CUPIC) (Hezode C et al)
Ribavirin Dose Modification in Treatment-Naive and Previously Treated Patients who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies (Sulkowski MS et al)
A Randomized Trial Comparing Ribavirin Dose Reduction Versus Erythropoietin for Anemia Management in Previously Untreated Patients with Chronic Hepatitis C Receiving Boceprevir Plus Peginterferon/RIBA (Poordad FF et al)
Efficacy and Safety of Anticoagulation in Patients with Cirrhosis and Portal Vein Thrombosis (Seijo S et al)
Impact of HCV Treatment and Disease Severity on Health Care Costs in Chronic HCV Patients: Analysis of a Large U.S. Private Health Insurance Claims Database (Gordon SC et al)
ATOMIC: 97% RVR for PSI-7977 + PEG/RBV x 12 Week Regimen in HCV GT1: An End to Response-Guided Therapy? (Kowdley et al)
ELECTRON: Once Daily PSI-7977 Plus RBV in HCV GT1/2/3 (Gane EJ et al)
12-Week Interferon-Free Regimen of ABT-450/R + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naive HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders (Poordad F et al
Potent Viral Suppression with All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/- Ribavirin, in Treatment-Naïve Patients with Chronic HCV GT1, 2, or 3 (Sulkowski M et al
Click here to view comments and abstracts
No comments:
Post a Comment